淀粉样蛋白与Tau蛋白正电子发射断层扫描信号升高与无认知障碍老年人近近期阿尔茨海默病症状发展的关联
这项纵向队列研究纳入4个独立人群队列共580名无认知障碍老年人,基于淀粉样蛋白(A)和Tau蛋白(T)PET将参与者分为A+T+、A+T-、A-T+、A-T-四组。A+T+组中33%至83%在随访期间进展为轻度认知障碍,限制于A+T+(N+)个体时进展比例进一步升至43%至100%,而其他生物标志物组进展比例低于20%。
要点
- A+T+组进展为轻度认知障碍的风险比(HR)较其他生物标志物组均≥5。
- A+T+(N+)的无认知障碍老年人多数在2至3年内出现阿尔茨海默病症状。
- 许多A+T+未进展者亦显示纵向认知下降,其他组认知轨迹主要保持稳定。
核心结论
- NIA-AA研究标准的临床预后价值在4个独立队列中得到证实,多数A+T+(N+)无认知障碍老年人在2至3年内出现阿尔茨海默病症状。
研究设计与样本
- 纵向队列研究,使用PREVENT-AD、HABS、AIBL和Knight ADRC共4个独立人群队列2003年至2021年收集的数据,纳入580名无认知障碍老年人,PET后中位临床随访1.94至3.66年。
主要发现
- A+T+组中33%至83%进展为轻度认知障碍(平均进展时间2至2.72年),其他生物标志物组进展比例低于20%。
- 限制于A+T+(N+)个体时,进展比例进一步升至43%至100%。
- A+T+组较其他生物标志物组进展为轻度认知障碍的Cox比例风险比均≥5。
- 许多A+T+未进展者亦显示纵向认知下降,其他组认知轨迹主要保持稳定。
关键数值与推荐
- 基于全局淀粉样蛋白负荷(A)和Tau蛋白PET摄取颞叶复合区域(T)的二元评估,将参与者分为A+T+、A+T-、A-T+、A-T-四组。
- 神经变性(N)的存在(+)或缺失(-)通过颞叶皮层厚度评估。
- 主要结局为临床进展至轻度认知障碍,在Knight ADRC中通过临床痴呆评定量表评分≥0.5识别,其他队列通过共识委员会审查识别,临床评估者对影像、遗传和体液生物标志物数据设盲。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: National Institute on Aging-Alzheimer's Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer disease (AD). OBJECTIVE: To assess the clinical value of these biological criteria to identify older individuals without cognitive impairment who are at near-term risk of developing symptomatic AD. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort study used data from 4 independent population-based cohorts (PREVENT-AD, HABS, AIBL, and Knight ADRC) collected between 2003 and 2021. Participants were older adults without cognitive impairment with 1 year or more of clinical observation after amyloid β and tau positron emission tomography (PET). Median clinical follow-up after PET ranged from 1.94 to 3.66 years. EXPOSURES: Based on binary assessment of global amyloid burden (A) and a composite temporal region of tau PET uptake (T), participants were stratified into 4 groups (A+T+, A+T-, A-T+, A-T-). Presence (+) or absence (-) of neurodegeneration (N) was assessed using temporal cortical thickness. MAIN OUTCOMES AND MEASURES: Each cohort was analyzed separately. Primary outcome was clinical progression to mild cognitive impairment (MCI), identified by a Clinical Dementia Rating score of 0.5 or greater in Knight ADRC and by consensus committee review in the other cohorts. Clinical raters were blind to imaging, genetic, and fluid biomarker data. A secondary outcome was cognitive decline, based on a slope greater than 1.5 SD below the mean of an independent subsample of individuals without cognitive impairment. Outcomes were compared across the biomarker groups. RESULTS: Among 580 participants (PREVENT-AD, 128; HABS, 153; AIBL, 48; Knight ADRC, 251), mean (SD) age ranged from 67 (5) to 76 (6) years across cohorts, with between 55% (137/251) and 74% (95/128) female participants. Across cohorts, 33% to 83% of A+T+ participants progressed to MCI during follow-up (mean progression time, 2-2.72 years), compared with less than 20% of participants in other biomarker groups. Progression further increased to 43% to 100% when restricted to A+T+(N+) individuals. Cox proportional hazard ratios for progression to MCI in the A+T+ group vs other biomarker groups were all 5 or greater. Many A+T+ nonprogressors also showed longitudinal cognitive decline, while cognitive trajectories in other groups remained predominantly stable. CONCLUSIONS AND RELEVANCE: The clinical prognostic value of NIA-AA research criteria was confirmed in 4 independent cohorts, with most A+T+(N+) older individuals without cognitive impairment developing AD symptoms within 2 to 3 years.
引用
- Strikwerda-Brown C, Hobbs DA, Gonneaud J, et al. Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. JAMA Neurol. 2022. PMID: 35907254. doi:10.1001/jamaneurol.2022.2379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。